The RISC Study

Relationship between Insulin Sensitivity and Cardiovascular disease: Status at 30 October 2008

The RISC (Relationship between Insulin Sensitivity and Cardiovascular disease) Study is being carried out in 19 European recruiting centres to examine whether insulin sensitivity (directly measured with the euglycaemic clamp technique) predicts cardiovascular disease (CVD) independently of other factors.

The study makes use of ultrasound scans of the carotid artery and takes the thickness of the intima-media layer in the artery wall (IMT) as an early marker of atherosclerosis. The study is being carried out across Europe and is the largest study to date to use the clamp technique to measure insulin sensitivity in healthy people.

 

RISC objectives

The primary objective of RISC is to establish whether insulin resistance predicts (in healthy people with no signs or symptoms of disease) the deterioration of CVD risk markers, diabetes, obesity, atherosclerosis, dyslipidaemia, and clinical CVD.

Secondary objectives are:1) to analyse genetic and environmental contributions to insulin resistance and CVD and 2) to develop and validate, against the clamp, a method for the assessment of insulin sensitivity based on the oral glucose tolerance test.

 

Baseline study

At the end of November 2004, the RISC study had recruited 1504 participants in 14 countries (Austria, Denmark, Finland, France, Germany, Greece, The Netherlands, Ireland, Italy, Sweden, Spain, Switzerland, United Kingdom and Serbia and Montenegro). Of these 1340 underwent the 'clamp' study and became part of the RISC population of which 1081 have completed the year 3 follow up.

The measures carried out in these volunteers included:

 

Characteristics of the RISC participants

 

Summary of work to date

Data has been collected on 1340 men and women who underwent the euglycaemic hyperinsulinaemic clamp (406 with additional measures of hepatic glucose production from the tracer studies) and carotid artery IMT measurement (as well as the other tests indicated above).

These participants form the core group that are being telephoned at yearly intervals and have been invited back for examinations after 3 years. Year 3 follow up examination data are now included for 1085 participants (30/10/2008). Follow up is now completed.

Publications are being produced with RISC data. Click here to see list of publications. A major symposium was held at the EASD in Amsterdam September 2007. Webcast can be accessed on Publications page. The RISC project is planned to continue at least until 2010.

 

Follow up and examinations at Year 3

RISC has competed the Year 3 follow up examinations. Participants have been contacted to invite them to undergo all the original tests except for the clamp and physical activity monitor. The participants are being telephoned at 4 years to update about health status and medication.

 

Preliminary findings

Abstracts and manuscripts have been prepared after preliminary examination of the data and these are listed on the publications page.

Press release from RISC Study: 3 September 2004: download here

Press release from RISC Study: 19 September 2007: download here

 

 

Newsletter for RISC participants August 2007 pdf file

The RISC Study is supported by EU FP5 contract: QLG1-CT-2001-01252 and by AstraZeneca. The EGIR group is supported by Merck-Serono.

 

Updated by Lucrecia Mota 26 March 2009